May 25, 2017
Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics
Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising $45 million.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
May 25, 2017
FDA OK’s Roche’s arteritis drug
The U.S. Food and Drug Administration (FDA) has approved Roche’s Actemra/RoActemra (tocilizumab) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition.
May 25, 2017
Therapix Biosciences looks for new CEO
Therapix Biosciences, a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-based drugs, has announced that the company’s Chief Executive Officer Dr. Elran Haber will step down from his position to pursue other professional opportunities.
May 24, 2017
FDA Advisory Committee recommends approval of Emmaus Life Sciences’s sickle cell disease drug
The Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of Emmaus Life Sciences’s Endari for the treatment of sickle cell disease (SCD) is favorable.
May 24, 2017
UK biotech boasts Europe’s best pipeline as Brexit threat looms
Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.
May 24, 2017
Bioverativ buys San Francisco-based True North Therapeutics
Bioverativ has acquired South San Francisco-based True North Therapeutics, a privately-held, clinical-stage rare disease biotechnology company, for an upfront payment of $400 million plus assumed cash.
May 24, 2017
Kristin Chenoweth kicks off Allergan’s skin disease awareness campaign
Emmy and Tony award-winning actress and singer, Kristin Chenoweth will kick off Allergan’s “Less Red, More You” campaign at an exclusive event in New York City.
May 23, 2017
Horizon Pharma and Chiesi Farmaceutici in European marketing rights agreement
Horizon Pharma has reached an agreement to sell a European subsidiary that owns the marketing rights to Procysbi (cysteamine bitartrate) delayed-release capsules and Quinsair (levofloxacin inhalation solution) in Europe, the Middle East and Africa (EMEA) regions to Chiesi Farmaceutici S.p.A. (Chiesi) for an upfront payment of $70 million, with additional potential milestone payments based on sales targets.
May 23, 2017
Selexis and OSE Immunotherapeutics in commercial agreement
Selexis SA and OSE Immunotherapeutics have signed a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform.
May 23, 2017
New bosses named in Summit Therapeutics
Summit Therapeutics, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection (‘CDI’), has appointed Dr David Roblin as Chief Medical Officer, Anne Heatherington, PhD, as Head of Clinical Development and Quantitative Sciences and Dave Powell, PhD, as Head of Research.